Literature DB >> 15238429

Association of immune abnormalities with telomere shortening in autosomal-dominant dyskeratosis congenita.

Matt Knudson1, Shashikant Kulkarni, Zuhair K Ballas, Monica Bessler, Frederick Goldman.   

Abstract

Dyskeratosis congenita (DC) is an inherited bone marrow failure disorder characterized by abnormal skin pigmentation and nail dystrophy. We have recently described, in 10 members of a large 3-generation family, an autosomal-dominant form of DC (AD DC) that is due to a mutation in the gene-encoding human telomerase RNA (TERC), resulting in telomere shortening. In studying the immunologic consequences of TERC mutations, severe B lymphopenia and decreased immunoglobulin M (IgM) levels were noted. T cells were found to overexpress senescent markers, including CD57 and Fas receptor, and were moderately reduced in cell number. To determine whether these in vivo findings were related to cellular replicative defects, short-term cultures of AD DC lymphocytes were established to measure proliferation, mitoses, and apoptosis. AD DC lymphocytes displayed a markedly reduced proliferative capacity and increased basal apoptotic rate. Finally, telomere shortening was most prominent in third-generation subjects, and there appeared to be a correlation between telomere length and in vivo and in vitro immune findings. In summary, the observed lymphopenia and hypogammaglobulinemia in AD DC is likely a consequence of replicative failure and premature senescence of lymphocytes, supporting a role of telomerase activity in immune homeostasis.

Entities:  

Mesh:

Year:  2004        PMID: 15238429     DOI: 10.1182/blood-2004-04-1673

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

Review 1.  Telomere and adaptive immunity.

Authors:  Nan-ping Weng
Journal:  Mech Ageing Dev       Date:  2007-12-08       Impact factor: 5.432

Review 2.  Flow Cytometry, a Versatile Tool for Diagnosis and Monitoring of Primary Immunodeficiencies.

Authors:  Roshini S Abraham; Geraldine Aubert
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

Review 3.  Senescence of hematopoietic stem cells and bone marrow failure.

Authors:  Jichun Chen
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

4.  Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis.

Authors:  Chad A Newton; David Zhang; Justin M Oldham; Julia Kozlitina; Shwu-Fan Ma; Fernando J Martinez; Ganesh Raghu; Imre Noth; Christine Kim Garcia
Journal:  Am J Respir Crit Care Med       Date:  2019-08-01       Impact factor: 21.405

5.  An antiapoptotic role for telomerase RNA in human immune cells independent of telomere integrity or telomerase enzymatic activity.

Authors:  Francesca S Gazzaniga; Elizabeth H Blackburn
Journal:  Blood       Date:  2014-10-15       Impact factor: 22.113

6.  Lung transplantation for pulmonary fibrosis in dyskeratosis congenita: Case Report and systematic literature review.

Authors:  Neelam Giri; Rees Lee; Albert Faro; Charles B Huddleston; Frances V White; Blanche P Alter; Sharon A Savage
Journal:  BMC Blood Disord       Date:  2011-06-15

7.  Dyskeratosis Congenita Dermal Fibroblasts are Defective in Supporting the Clonogenic Growth of Epidermal Keratinocytes.

Authors:  Erin M Buckingham; Frederick D Goldman; Aloysius J Klingelhutz
Journal:  Aging Dis       Date:  2012-10-12       Impact factor: 6.745

Review 8.  T cell replicative senescence in human aging.

Authors:  Jennifer P Chou; Rita B Effros
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 9.  Cancer in dyskeratosis congenita.

Authors:  Blanche P Alter; Neelam Giri; Sharon A Savage; Philip S Rosenberg
Journal:  Blood       Date:  2009-03-12       Impact factor: 22.113

10.  Short telomeres are sufficient to cause the degenerative defects associated with aging.

Authors:  Mary Armanios; Jonathan K Alder; Erin M Parry; Baktiar Karim; Margaret A Strong; Carol W Greider
Journal:  Am J Hum Genet       Date:  2009-12       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.